CombinatoRx Singapore Pte Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CombinatoRx Singapore Pte Ltd.
STOCKWATCH: Name, Platform; Time of death, December 2013
They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around their portfolios to off-load risk and negative cash flows onto the public markets from investments that weren't formed five minutes ago, then we see the platform companies.
Zalicus slumps as another lead candidate bites the dust
Zalicus' lead drug candidate Z160 has failed in two Phase II chronic pain trials, prompting the company to terminate its development. The news sent the company's share price into a nose dive. It closed 72% down at $1.30 on the news (11 November).
Zalicus shifts focus to pain after lead project Synavive fails in arthritis
It's on to plan B for Zalicus, which saw its stock price drop 43.2% to $0.79 per share on 10 September after the company announced that it is dropping development of its lead drug candidate, Synavive, due to a lack of clinically meaningful benefit for rheumatoid arthritis (RA) patients in a Phase IIb study.
Third Rock's $40M bet on Blueprint's rapid quest to personalise cancer therapies
"Our vision is to transform certain cancers into manageable conditions." So says, founding president and CEO of Blueprint Medicines, Chris Varma.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice